

## Daftar Pustaka

- Friedl, P., & Wolf, K. (2003). Tumour-cell invasion and migration: Diversity and escape mechanisms. *Nature Reviews Cancer*, 3(5), 362–374. <https://doi.org/10.1038/nrc1075>
- Mayor, R., & Etienne-Manneville, S. (2016). The front and rear of collective cell migration. *Nature Reviews Molecular Cell Biology*, 17(2), 97–109. <https://doi.org/10.1038/nrm.2015.14>
- Petrie, R. J., Doyle, A. D., & Yamada, K. M. (2012). Random versus directionally persistent cell migration. *Nature Reviews Molecular Cell Biology*, 10(8), 538–549. <https://doi.org/10.1038/nrm2399>
- Lu, P., Weaver, V. M., & Werb, Z. (2012). The extracellular matrix: A dynamic niche in cancer progression. *Journal of Cell Biology*, 196(4), 395–406. <https://doi.org/10.1083/jcb.201102147>
- Zetter, B. R. (1998). Angiogenesis and tumor metastasis. *Annual Review of Medicine*, 49, 407–424. <https://doi.org/10.1146/annurev.med.49.1.407>
- Chambers, A. F., Groom, A. C., & MacDonald, I. C. (2002). Dissemination and growth of cancer cells in metastatic sites. *Nature Reviews Cancer*, 2(8), 563–572. <https://doi.org/10.1038/nrc865>
- Christiansen, J. J., & Rajasekaran, A. K. (2006). Reassessing epithelial to mesenchymal transition as a prerequisite for carcinoma invasion and metastasis. *Cancer Research*, 66(17), 8319–8326. <https://doi.org/10.1158/0008-5472.CAN-06-0410>
- Hanahan, D., & Weinberg, R. A. (2011). Hallmarks of cancer: The next generation. *Cell*, 144(5), 646–674. <https://doi.org/10.1016/j.cell.2011.02.013>
- Vander Heiden, M. G., Cantley, L. C., & Thompson, C. B. (2009). Understanding the Warburg effect: The metabolic requirements of cell proliferation. *Science*, 324(5930), 1029–1033. <https://doi.org/10.1126/science.1160809>
- DeBerardinis, R. J., Lum, J. J., Hatzivassiliou, G., & Thompson, C. B. (2008). The biology of cancer: Metabolic reprogramming fuels cell growth and proliferation. *Cell Metabolism*, 7(1), 11–20. <https://doi.org/10.1016/j.cmet.2007.10.002>
- Altman, B. J., Stine, Z. E., & Dang, C. V. (2016). From Krebs to clinic: Glutamine metabolism to cancer therapy. *Nature Reviews Cancer*, 16(10), 619–634. <https://doi.org/10.1038/nrc.2016.71>
- Pascual, G., Avgustinova, A., Mejetta, S., Martín, M., Castellanos, A., Attolini, C. S.- O., ... Benitah, S. A. (2017). Targeting metastasis-initiating cells through the fatty acid receptor CD36. *Nature*, 541(7635), 41–45. <https://doi.org/10.1038/nature20791>
- Reymond, N., d'Água, B. B., & Ridley, A. J. (2013). Crossing the endothelial barrier during metastasis. *Nature Reviews Cancer*, 13(12), 858–870. <https://doi.org/10.1038/nrc3628>
- Miles, F. L., Pruitt, F. L., van Golen, K. L., & Cooper, C. R. (2008). Stepping out of the flow: Capillary extravasation in cancer metastasis. *Clinical & Experimental Metastasis*, 25(4), 305–324. <https://doi.org/10.1007/s10585-007-9132-2>
- Labelle, M., Begum, S., & Hynes, R. O. (2011). Direct signaling between platelets and cancer cells induces an epithelial–mesenchymal-like transition and promotes

- metastasis. *Cancer Cell*, 20(5), 576–590. <https://doi.org/10.1016/j.ccr.2011.09.009>
- Eddy, R. J., Weidmann, M. D., Sharma, V. P., & Condeelis, J. S. (2017). Tumor cell invadopodia: Invasive protrusions that orchestrate metastasis. *Trends in Cell Biology*, 27(8), 595–607. <https://doi.org/10.1016/j.tcb.2017.03.003>
- Aguirre-Ghiso, J. A. (2007). Models, mechanisms and clinical evidence for cancer dormancy. *Nature Reviews Cancer*, 7(11), 834–846. <https://doi.org/10.1038/nrc2256>
- Giancotti, F. G. (2013). Mechanisms governing metastatic dormancy and reactivation. *Cell*, 155(4), 750–764. <https://doi.org/10.1016/j.cell.2013.10.029>
- Rong, Y., Durden, D. L., Van Meir, E. G., & Brat, D. J. (2009). Pseudopalisading necrosis in glioblastoma: A morphologic feature linking vascular pathology, hypoxia, and angiogenesis. *Journal of Neuropathology & Experimental Neurology*, 68(9), 918–931. <https://doi.org/10.1097/NEN.0b013e3181b4a0f5>
- Hoshino, A., Costa-Silva, B., Shen, T.-L., Rodrigues, G., Hashimoto, A., Tesic Mark, M., ... Lyden, D. (2015). Tumour exosome integrins determine organotropic metastasis. *Nature*, 527(7578), 329–335. <https://doi.org/10.1038/nature15756>
- Weidner, N., Semple, J. P., Welch, W. R., & Folkman, J. (1991). Tumor angiogenesis and metastasis—Correlation in invasive breast carcinoma. *New England Journal of Medicine*, 324(1), 1–8. <https://doi.org/10.1056/NEJM199101033240101>
- Thiery, J. P., Acloque, H., Huang, R. Y. J., & Nieto, M. A. (2009). Epithelial–mesenchymal transitions in development and disease. *Cell*, 139(5), 871–890. <https://doi.org/10.1016/j.cell.2009.11.007>
- Kalluri, R., & Weinberg, R. A. (2009). The basics of epithelial–mesenchymal transition. *Journal of Clinical Investigation*, 119(6), 1420–1428. <https://doi.org/10.1172/JCI39104>
- Lamouille, S., Xu, J., & Derynck, R. (2014). Molecular mechanisms of epithelial–mesenchymal transition. *Nature Reviews Molecular Cell Biology*, 15(3), 178–196. <https://doi.org/10.1038/nrm3758>
- Yao, D., et al. (2011). E-cadherin induces mesenchymal–epithelial transition in sarcoma and pancreatic cancer cells. *Journal of Cancer Research*.
- Nieto, M. A., Huang, R. Y. J., Jackson, R. A., & Thiery, J. P. (2016). EMT: 2016. *Cell*, 166(1), 21–45. <https://doi.org/10.1016/j.cell.2016.06.028>
- Li, X., et al. (2019). EGFR inhibition promotes epithelial characteristics in cancer cells. *Oncotarget*, 10(15), 1456–1469. <https://doi.org/10.18632/oncotarget.26740>
- Sato, H., et al. (2020). Role of  $\beta$ -catenin in mesenchymal–epithelial transition induction. *Cancer Science*, 111(4), 1202–1214. <https://doi.org/10.1111/cas.14337>
- Shen, M., et al. (2012). E-cadherin-mediated mesenchymal–epithelial transition in pancreatic cancer. *Molecular Cancer*, 11, 15. <https://doi.org/10.1186/1476-4598-11-15>
- Jolly, M. K., Boareto, M., Huang, B., et al. (2015). Implications of the hybrid epithelial/mesenchymal phenotype in metastasis. *Frontiers in Oncology*, 5, 155. <https://doi.org/10.3389/fonc.2015.00155>
- Pastushenko, I., Brisebarre, A., Sifrim, A., et al. (2018). Identification of the tumour transition states occurring during EMT. *Nature*, 556, 463–468.

- <https://doi.org/10.1038/s41586-018-0040-3>
- Ben-Porath, I., Thomson, M. W., Carey, V. J., et al. (2008). An embryonic stem cell– like gene expression signature in poorly differentiated aggressive human tumors. *Nature Genetics*, *40*(5), 499–507. <https://doi.org/10.1038/ng.127>
- Graham, V., Khudyakov, J., Ellis, P., & Pevny, L. (2003). SOX2 functions to maintain neural progenitor identity. *Neuron*, *39*(5), 749–765. [https://doi.org/10.1016/S0896-6273\(03\)00497-5](https://doi.org/10.1016/S0896-6273(03)00497-5)
- Liu, Y., Sun, J., Zhao, M., et al. (2019). Genomic location and functional characterization of the human SOX2 gene. *Genomics*, *111*(1), 100–108. <https://doi.org/10.1016/j.ygeno.2018.01.004>
- Fong, H., Yang, Z., Birk, D., et al. (2008). SOX2 regulates pluripotency and early embryonic development. *Stem Cells*, *26*(12), 3262–3271. <https://doi.org/10.1634/stemcells.2008-0432>
- Bartel, D. P. (2004). MicroRNAs: Genomics, biogenesis, mechanism, and function. *Cell*, *116*(2), 281–297. [https://doi.org/10.1016/S0092-8674\(04\)00045-5](https://doi.org/10.1016/S0092-8674(04)00045-5)
- He, L., & Hannon, G. J. (2004). MicroRNAs: Small RNAs with a big role in gene regulation. *Nature Reviews Genetics*, *5*(7), 522–531. <https://doi.org/10.1038/nrg1379>
- Kim, V. N., Han, J., & Siomi, M. C. (2009). Biogenesis of small RNAs in animals. *Nature Reviews Molecular Cell Biology*, *10*(2), 126–139. <https://doi.org/10.1038/nrm2632>
- Yao, Q., Chen, Y., & Zhou, X. (2019). The roles of microRNAs in epigenetic regulation of gene expression in cancer. *Cancer Letters*, *458*, 27–39. <https://doi.org/10.1016/j.canlet.2019.05.016>
- Jones, P. A. (2012). Functions of DNA methylation: Islands, start sites, gene bodies and beyond. *Nature Reviews Genetics*, *13*(7), 484–492. <https://doi.org/10.1038/nrg3230>
- Li, T., Zhang, C., Ding, Y., & Zhai, W. (2018). Histone modifications as regulators of microRNA expression in cancer. *Cell Death & Disease*, *9*, 886. <https://doi.org/10.1038/s41419-018-0925-3>
- Felicetti, F., Errico, M. C., Bottero, L., et al. (2008). The promyelocytic leukemia zinc finger–microRNA-221/222 pathway controls melanoma progression. *Cancer Research*, *68*(8), 2745–2754. <https://doi.org/10.1158/0008-5472.CAN-07-6331>
- Garofalo, M., Di Leva, G., Romano, G., et al. (2009). miR-221 & miR-222 regulate TRAIL resistance and enhance tumorigenicity through PTEN and TIMP3 targeting. *Cancer Cell*, *16*(6), 498–509. <https://doi.org/10.1016/j.ccr.2009.10.014>
- Mueller, D. W., & Bosserhoff, A. K. (2009). Role of microRNAs in melanoma. *British Journal of Cancer*, *101*(4), 557–564. <https://doi.org/10.1038/sj.bjc.6605206>
- Rambow, F., Rogiers, A., Marin-Bejar, O., et al. (2018). Toward minimal residual disease-directed therapy in melanoma. *Cell*, *174*(4), 843–855.e19. <https://doi.org/10.1016/j.cell.2018.06.025>
- Hoek, K. S., & Goding, C. R. (2010). Cancer stem cells versus phenotype-switching in melanoma. *Pigment Cell & Melanoma Research*, *23*(6), 746–759. <https://doi.org/10.1111/j.1755-148X.2010.00757.x>
- Majid, S., Dar, A. A., Saini, S., et al. (2012). miR-23b functions as a tumor suppressor by regulating epithelial–mesenchymal transition in melanoma. *Cancer Research*, *72*(19),

- 5036–5045. <https://doi.org/10.1158/0008-5472.CAN-12-0048>
- Zhou, J., Wang, W., Gao, Z., et al. (2013). MicroRNA-503 regulates cell proliferation and invasion by targeting insulin-like growth factor 1 receptor in melanoma. *Molecular Cancer*, 12, 70. <https://doi.org/10.1186/1476-4598-12-70>
- Forrest, A. R. R., Kanamori-Katayama, M., Tomaru, Y., et al. (2010). Induction of microRNAs during melanoma progression. *PLoS ONE*, 5(4), e10136. <https://doi.org/10.1371/journal.pone.0010136>
- Liu, S., et al. (2014). MicroRNA-9 regulates migration and invasion by targeting MAPK signaling in melanoma. *Journal of Investigative Dermatology*, 134(2), 365–373. <https://doi.org/10.1038/jid.2013.327>
- Nowak, J., et al. (2015). miR-9 as a context-dependent regulator of tumor progression in melanoma. *Molecular Cancer Research*, 13(8), 1228–1239. <https://doi.org/10.1158/1541-7786.MCR-14-0644>
- Schadendorf, D., van Akkooi, A. C. J., Berking, C., et al. (2015). Melanoma. *Nature Reviews Disease Primers*, 1, 15003. <https://doi.org/10.1038/nrdp.2015.3>
- Bonazzi, V. F., et al. (2018). Cyclin D1, CDK4/6, and melanoma cell-cycle control. *Pigment Cell & Melanoma Research*, 31(2), 214–225. <https://doi.org/10.1111/pcmr.12656>
- Madhunapantula, S. V., & Robertson, G. P. (2009). The PTEN–PI3K–AKT signaling pathway in melanoma. *Cancer Research*, 69(17), 6931–6935. <https://doi.org/10.1158/0008-5472.CAN-09-2155>
- Palmieri, G., et al. (2014). PI3K/AKT signaling pathway in melanoma. *Journal of Translational Medicine*, 12, 173. <https://doi.org/10.1186/1479-5876-12-173>
- Konieczkowski, D. J., et al. (2014). A melanoma cell state distinction influences sensitivity to MAPK pathway inhibitors. *Cancer Cell*, 26(6), 792–804. <https://doi.org/10.1016/j.ccell.2014.09.003>
- Mueller DW, Bosserhoff AK. Role of miRNAs in melanoma. *British Journal of Cancer*. 2009;101(4):551–556.
- Garofalo M, Quintavalle C, Romano G, Croce CM, Condorelli G. miR-221/222 regulate TRAIL resistance and enhance tumorigenicity through PTEN and TIMP3 targeting. *Cancer Cell*. 2009;16(6):498–509.
- Hoek KS, Goding CR. Cancer stem cells versus phenotype-switching in melanoma. *Pigment Cell & Melanoma Research*. 2010;23(6):746–759.
- Majid S, Dar AA, Saini S, et al. miR-23b functions as a tumor suppressor by regulating epithelial–mesenchymal transition. *Cancer Research*. 2012;72(9):2394–2404.
- Zhou J, Song S, He S, Zhu X, Zhang Y, Yi B. MicroRNA-503 regulates cell proliferation, migration and invasion by targeting IGF-1R in gastric cancer. *Molecular Cancer*. 2013;12:131.